Send to

Choose Destination
See comment in PubMed Commons below
Genet Med. 2005 Feb;7(2):105-10.

Individualization of long-term enzyme replacement therapy for Gaucher disease.

Author information

Human Genetics Program, Hayward Genetics Center, Tulane University Medical School, New Orleans, Louisiana, USA.

Erratum in

  • Genet Med. 2005 Sep;7(7):514. Prakesh-Cheng, Ainu [corrected to Prakash-Cheng, Ainu].
  • Genet Med. 2005 Jul-Aug;7(6):460.


Gaucher disease, the most common lysosomal storage disorder, is a heterogeneous condition affecting multiple organ systems. Patients with nonneuronopathic (type 1) Gaucher disease may suffer from hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Enzyme replacement therapy (ERT) with mannose-terminated glucocerebrosidase (imiglucerase, Cerezyme, Genzyme Corporation, Cambridge, MA) reverses or ameliorates many of the manifestations of type 1 Gaucher disease. However, due to the variable pattern and severity of disease, and the uncertain manner of progression, implementation of treatment, choice of initial and maintenance imiglucerase dose, and evaluation of the therapeutic response must be tailored to the individual patient. For the past 14 years, the US Regional Coordinators of the International Collaborative Gaucher Group have individually and collectively developed extensive clinical experience in managing patients with Gaucher disease. In this review, we present recommendations for initial imiglucerase treatment and subsequent dose adjustments based on a schedule of regular assessment and monitoring, and achievement and maintenance of defined therapeutic goals.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons


    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center